Aspirin/hydrochlorothiazide/enalapril/atorvastatin - Alborz-Darou Pharmaceutical

Drug Profile

Aspirin/hydrochlorothiazide/enalapril/atorvastatin - Alborz-Darou Pharmaceutical

Alternative Names: PolyIran 1; PolyPill 4-1

Latest Information Update: 25 Nov 2015

Price : $50

At a glance

  • Originator Alborz Darou
  • Developer Alborz Darou; Golestan University of Medical Sciences; Tehran University of Medical Sciences; University of Birmingham
  • Class Antihyperlipidaemics; Antihypertensives; Antiplatelets; Cardiovascular therapies; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Salicylates; Small molecules
  • Mechanism of Action ACE inhibitors; Cyclooxygenase inhibitors; HMG-CoA reductase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Cardiovascular disorders

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top